1. Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer:Chemotherapy or Chemoradiotherapy?
- Author
-
Eva Versteijne, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Martijn P. W. Intven, Joost M. Klaase, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, and Geertjan van Tienhoven
- Subjects
neoadjuvant treatment ,Cancer Research ,RESECTION ,borderline resectable pancreatic cancer (BRPC) ,MULTICENTER ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,DUCTAL ADENOCARCINOMA ,CONCURRENT RADIATION ,OPEN-LABEL ,chemotherapy ,UPFRONT SURGERY ,THERAPY ,CHEMORADIATION ,ADJUVANT CHEMOTHERAPY ,Oncology ,SDG 3 - Good Health and Well-being ,FULL-DOSE GEMCITABINE ,resectable pancreatic cancer (RPC) ,radiotherapy ,RC254-282 - Abstract
Worldwide, there is a shifting paradigm from immediate surgery with adjuvant treatment to a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer (RPC or BRPC). Comparison of neoadjuvant and adjuvant studies is extremely difficult because of a great difference in patient selection. The evidence from randomized studies shows that overall survival by intention-to-treat improves after neoadjuvant gemcitabine-based chemoradiotherapy or chemotherapy (various regimens), as compared to immediate surgery followed by adjuvant chemotherapy. Radiotherapy appears to play an important role in mediating locoregional effects. Yet, since more effective chemotherapy regimens are currently available, in particular FOLFIRINOX and Gemcitabine/Nab-paclitaxel, these chemotherapy regimens should be investigated in future randomized trials combined with (stereotactic) radiotherapy to further improve outcomes of RPC and BRPC.
- Published
- 2022
- Full Text
- View/download PDF